BioWorld

July 29, 2004

Cell Therapeutics Adds To Cash With $42.8M Offering

Laden with the expense of pivotal trials, Cell Therapeutics Inc. raised $42.8 million to give it the reserves to last through 2005. (BioWorld Today) Read More

With Antegren Launch Expected, Biogen Idec Tops 2Q Estimates

MannKind IPO Prices Within Range; Shares Close Higher

New BioDefense Guide Released With 37 Company Success Stories

Lexicon, Takeda In Agreement For High Blood Pressure Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 12, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...